Literature DB >> 24709252

Niosomes from glucuronic acid-based surfactant as new carriers for cancer therapy: preparation, characterization and biological properties.

Lorena Tavano1, Rossana Aiello2, Giuseppina Ioele3, Nevio Picci3, Rita Muzzalupo4.   

Abstract

Niosomes are vesicular systems composed of surfactant molecules, claimed to be used as drug delivery carriers thanks to their physico-chemical and biological properties. The aim of this work was to design niosomes obtained with a surfactant synthesized from glucuronic acid. Doxorubicin and 5FU were used as model drugs. Niosomes were prepared with different ratios between surfactant and cholesterol, and characterized in terms of size, morphology, drugs entrapment efficiency and in vitro releases, to identify the optimal formulation to be used in pharmaceutical fields. In addition, the hemolytic activity of all formulations have been also evaluated. Results showed that dodecylglucuronamide surfactant was able to produce vesicular systems with or without the presence of cholesterol. Niosomes resulted regular in size and shape and they have been found to encapsulate and release in a controlled manner both doxorubicin and 5-fluorouracil. Hemolytic tests showed that the capability of disrupting erythrocyte only depend on the size of colloidal aggregates. Finally, our formulations could be potentially used as antitumoral delivery systems in anticancer therapy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-Fluorouracil; Doxorubicin; Glucuronic acid; Hemolysis; Niosomes

Mesh:

Substances:

Year:  2014        PMID: 24709252     DOI: 10.1016/j.colsurfb.2014.03.016

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  8 in total

1.  Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.

Authors:  Fu-Rong Liu; Hui Jin; Yin Wang; Chen Chen; Ming Li; Sheng-Jun Mao; Qiantao Wang; Hui Li
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  The inhibitory effect of Acyclovir loaded nano-niosomes against herpes simplex virus type-1 in cell culture.

Authors:  Seyed Hamidreza Monavari; Mohammad Javad Mirzaei Parsa; Bahram Bolouri; Soltan Ahmed Ebrahimi; Angila Ataei-Pirkooh
Journal:  Med J Islam Repub Iran       Date:  2014-09-17

Review 3.  Current application of phytocompound-based nanocosmeceuticals for beauty and skin therapy.

Authors:  Palanivel Ganesan; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2016-05-11

4.  ATIQCTPC: a nanomedicine capable of targeting tumor and blocking thrombosis in vivo.

Authors:  Xinyi Xu; Yuji Wang; Jianhui Wu; Xi Hu; Haimei Zhu; Xiaoyi Zhang; Yaonan Wang; Lin Gui; Ming Zhao; Shiqi Peng
Journal:  Int J Nanomedicine       Date:  2017-06-13

5.  Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.

Authors:  Ashraf Alemi; Javad Zavar Reza; Fateme Haghiralsadat; Hossein Zarei Jaliani; Mojtaba Haghi Karamallah; Seyed Ahmad Hosseini; Somayeh Haghi Karamallah
Journal:  J Nanobiotechnology       Date:  2018-03-23       Impact factor: 10.435

Review 6.  Pulmonary route of administration is instrumental in developing therapeutic interventions against respiratory diseases.

Authors:  Xue Jin; Ling Song; Chao-Chao Ma; Yan-Chun Zhang; Shui Yu
Journal:  Saudi Pharm J       Date:  2020-11-04       Impact factor: 4.330

7.  Cyclodextrin modified niosomes to encapsulate hydrophilic compounds.

Authors:  Noelia D Machado; O Fernando Silva; Rita H de Rossi; Mariana A Fernández
Journal:  RSC Adv       Date:  2018-08-23       Impact factor: 4.036

8.  pH-Responsive PEGylated Niosomal Nanoparticles as an Active-Targeting Cyclophosphamide Delivery System for Gastric Cancer Therapy.

Authors:  Farnaz Khodabakhsh; Mahsa Bourbour; Mohammad Tavakkoli Yaraki; Saina Bazzazan; Haleh Bakhshandeh; Reza Ahangari Cohan; Yen Nee Tan
Journal:  Molecules       Date:  2022-08-24       Impact factor: 4.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.